Letters
Open Access
Concerns regarding the recommendation against prescribing selective serotonin reuptake inhibitors in the Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder
Anees Bahji, Marlon Danilewitz, Matthew Sloan, Victor Tang and David Crockford
CMAJ March 18, 2024 196 (10) E346-E347; DOI: https://doi.org/10.1503/cmaj.149917-l
Anees Bahji
Psychiatrist, Department of Psychiatry, University of Calgary, Calgary, Alta.
MDMarlon Danilewitz
Psychiatrist, Department of Psychiatry, University of Toronto, Toronto, Ont.
MDMatthew Sloan
Psychiatrist, Centre for Addiction and Mental Health, Toronto, Ont.
MSc MDVictor Tang
Psychiatrist, Centre for Addiction and Mental Health, Toronto, Ont.
MSc MDDavid Crockford
Psychiatrist, Department of Psychiatry, University of Calgary, Calgary, Alta.
MDIn this issue
Article extras
Article tools
Concerns regarding the recommendation against prescribing selective serotonin reuptake inhibitors in the Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder
Anees Bahji, Marlon Danilewitz, Matthew Sloan, Victor Tang, David Crockford
CMAJ Mar 2024, 196 (10) E346-E347; DOI: 10.1503/cmaj.149917-l
Concerns regarding the recommendation against prescribing selective serotonin reuptake inhibitors in the Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder
Anees Bahji, Marlon Danilewitz, Matthew Sloan, Victor Tang, David Crockford
CMAJ Mar 2024, 196 (10) E346-E347; DOI: 10.1503/cmaj.149917-l